Clinical characteristics, radiological features and outcomes in pulmonary involvement of cryoglobulinemia.
Alveolar hemorrhage
Cryoglobulinemia
Diffuse ground-glass opacity
Rituximab
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
02 May 2024
02 May 2024
Historique:
received:
15
10
2023
accepted:
28
03
2024
medline:
3
5
2024
pubmed:
3
5
2024
entrez:
2
5
2024
Statut:
epublish
Résumé
Cryoglobulinemia with pulmonary involvement is rare, and its characteristics, radiological findings, and outcomes are still poorly understood. Ten patients with pulmonary involvement of 491 cryoglobulinemia patients at Peking Union Medical College Hospital were enrolled in this retrospective study. We analyzed the characteristics, radiological features and management of pulmonary involvement patients, and compared with those of non-pulmonary involvement with cryoglobulinemia. The 10 patients with pulmonary involvement (2 males; median age, 53 years) included three patients with type I cryoglobulinemia and seven patients with mixed cryoglobulinemia. All of 10 patients were IgM isotype cryoglobulinemia. All type I patients were secondary to B-cell non-Hodgkin lymphoma. Four mixed patients were essential, and the remaining patients were secondary to infections (n = 2) and systemic lupus erythematosus (n = 1), respectively. Six patients had additional affected organs, including skin (60%), kidney (50%), peripheral nerves (30%), joints (20%), and heart (20%). The pulmonary symptoms included dyspnea (50%), dry cough (30%), chest tightness (30%), and hemoptysis (10%). Chest computed tomography (CT) showed diffuse ground-glass opacity (80%), nodules (40%), pleural effusions (30%), and reticulation (20%). Two patients experienced life-threatening diffuse alveolar hemorrhage. Five patients received corticosteroid-based regimens, and four received rituximab-based regimens. All patients on rituximab-based regimens achieved clinical remission. The estimated two-year overall survival (OS) was 40%. Patients with pulmonary involvement had significantly worse OS and progression-free survival than non-pulmonary involvement patients of cryoglobulinemia (P < 0.0001). A diagnosis of pulmonary involvement should be highly suspected for patients with cryoglobulinemia and chest CT-indicated infiltrates without other explanations. Patients with pulmonary involvement had a poor prognosis. Rituximab-based treatment may improve the outcome.
Sections du résumé
BACKGROUND
BACKGROUND
Cryoglobulinemia with pulmonary involvement is rare, and its characteristics, radiological findings, and outcomes are still poorly understood.
METHODS
METHODS
Ten patients with pulmonary involvement of 491 cryoglobulinemia patients at Peking Union Medical College Hospital were enrolled in this retrospective study. We analyzed the characteristics, radiological features and management of pulmonary involvement patients, and compared with those of non-pulmonary involvement with cryoglobulinemia.
RESULTS
RESULTS
The 10 patients with pulmonary involvement (2 males; median age, 53 years) included three patients with type I cryoglobulinemia and seven patients with mixed cryoglobulinemia. All of 10 patients were IgM isotype cryoglobulinemia. All type I patients were secondary to B-cell non-Hodgkin lymphoma. Four mixed patients were essential, and the remaining patients were secondary to infections (n = 2) and systemic lupus erythematosus (n = 1), respectively. Six patients had additional affected organs, including skin (60%), kidney (50%), peripheral nerves (30%), joints (20%), and heart (20%). The pulmonary symptoms included dyspnea (50%), dry cough (30%), chest tightness (30%), and hemoptysis (10%). Chest computed tomography (CT) showed diffuse ground-glass opacity (80%), nodules (40%), pleural effusions (30%), and reticulation (20%). Two patients experienced life-threatening diffuse alveolar hemorrhage. Five patients received corticosteroid-based regimens, and four received rituximab-based regimens. All patients on rituximab-based regimens achieved clinical remission. The estimated two-year overall survival (OS) was 40%. Patients with pulmonary involvement had significantly worse OS and progression-free survival than non-pulmonary involvement patients of cryoglobulinemia (P < 0.0001).
CONCLUSIONS
CONCLUSIONS
A diagnosis of pulmonary involvement should be highly suspected for patients with cryoglobulinemia and chest CT-indicated infiltrates without other explanations. Patients with pulmonary involvement had a poor prognosis. Rituximab-based treatment may improve the outcome.
Identifiants
pubmed: 38698461
doi: 10.1186/s13023-024-03159-0
pii: 10.1186/s13023-024-03159-0
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
185Subventions
Organisme : Beijing Natural Science Haidian Frontier Foundation
ID : L222081
Organisme : National High Level Hospital Clinical Research Funding
ID : 2022-PUMCH-A-193
Informations de copyright
© 2024. The Author(s).
Références
Damoiseaux J, Cohen Tervaert JW. Diagnostics and treatment of cryoglobulinaemia: it takes two to tango. Clin Rev Allergy Immunol. 2014;47(3):299–310.
doi: 10.1007/s12016-013-8390-y
pubmed: 24068540
Brouet JC, Clauvel JP, Danon F, Klein M, Seligmann M. Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med. 1974;57(5):775–88.
doi: 10.1016/0002-9343(74)90852-3
pubmed: 4216269
Sidana S, Rajkumar SV, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Dingli D, Kapoor P, Gonsalves WI, et al. Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia. Am J Hematol. 2017;92(7):668–73.
doi: 10.1002/ajh.24745
pubmed: 28370486
pmcid: 5579826
Harel S, Mohr M, Jahn I, Aucouturier F, Galicier L, Asli B, Malphettes M, Szalat R, Brouet JC, Lipsker D, et al. Clinico-biological characteristics and treatment of type I monoclonal cryoglobulinaemia: a study of 64 cases. Br J Haematol. 2015;168(5):671–8.
doi: 10.1111/bjh.13196
pubmed: 25363150
Ramos-Casals M, Forns X, Brito-Zerón P, Vargas A, Ruiz M, Laguno M, Yagüe J, Sánchez-Tapias JM, Gatell JM, Font J. Cryoglobulinaemia associated with hepatitis C virus: influence of HCV genotypes, HCV-RNA viraemia and HIV coinfection. J Viral Hepat. 2007;14(10):736–42.
doi: 10.1111/j.1365-2893.2007.00866.x
pubmed: 17875009
Trejo O, Ramos-Casals M, García-Carrasco M, Yagüe J, Jiménez S, de la Red G, Cervera R, Font J, Ingelmo M. Cryoglobulinemia: study of etiologic factors and clinical and immunologic features in 443 patients from a single center. Med (Baltim). 2001;80(4):252–62.
doi: 10.1097/00005792-200107000-00004
Ramos-Casals M, Stone JH, Cid MC, Bosch X. The cryoglobulinaemias. Lancet. 2012;379(9813):348–60.
doi: 10.1016/S0140-6736(11)60242-0
pubmed: 21868085
Desbois AC, Cacoub P, Saadoun D. Cryoglobulinemia: an update in 2019. Joint Bone Spine. 2019;86(6):707–13.
doi: 10.1016/j.jbspin.2019.01.016
pubmed: 30731128
Retamozo S, Díaz-Lagares C, Bosch X, Bové A, Brito-Zerón P, Gómez ME, Yagüe J, Forns X, Cid MC, Ramos-Casals M. Life-threatening cryoglobulinemic patients with Hepatitis C: clinical description and outcome of 279 patients. Med (Baltim). 2013;92(5):273–84.
doi: 10.1097/MD.0b013e3182a5cf71
Ramos-Casals M, Robles A, Brito-Zerón P, Nardi N, Nicolás JM, Forns X, Plaza J, Yagüe J, Sánchez-Tapias JM, Font J. Life-threatening cryoglobulinemia: clinical and immunological characterization of 29 cases. Semin Arthritis Rheum. 2006;36(3):189–96.
doi: 10.1016/j.semarthrit.2006.08.005
pubmed: 16996578
Motyckova G, Murali M. Laboratory testing for cryoglobulins. Am J Hematol. 2011;86(6):500–2.
doi: 10.1002/ajh.22023
pubmed: 21594887
Vermeersch P, Gijbels K, Knockaert D, Blockmans D, Westhovens R, Mariën G, Bossuyt X. Establishment of reference values for immunoglobulins in the cryoprecipitate. Clin Immunol. 2008;129(2):360–4.
doi: 10.1016/j.clim.2008.07.012
pubmed: 18757240
Zhang LL, Cao XX, Shen KN, Han HX, Zhang CL, Qiu Y, Zhao H, Gao XM, Feng J, Zhang L, et al. Clinical characteristics and treatment outcome of type I cryoglobulinemia in Chinese patients: a single-center study of 45 patients. Ann Hematol. 2020;99(8):1735–40.
doi: 10.1007/s00277-020-04123-1
pubmed: 32535708
Stanojevic S, Kaminsky DA, Miller MR, Thompson B, Aliverti A, Barjaktarevic I, Cooper BG, Culver B, Derom E, Hall GL et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. Eur Respir J 2022, 60(1).
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–90.
doi: 10.1182/blood-2016-01-643569
pubmed: 26980727
pmcid: 4874220
Aguiar MF, Faria-Janes AL, Garcia-Brandes GI, Takemi-Emori C, Ferraz MLG, Andrade LEC, de Souza AWS. Prevalence of cryoglobulinemia and cryoglobulinemic vasculitis in chronically HCV-infected Brazilian patients. Ann Hepatol. 2019;18(5):685–92.
doi: 10.1016/j.aohep.2019.04.010
pubmed: 31167733
Fiorini GF, Sinico RA, Winearls C, Custode P, De Giuli-Morghen C, D’Amico G. Persistent Epstein-Barr virus infection in patients with type II essential mixed cryoglobulinemia. Clin Immunol Immunopathol. 1988;47(3):262–9.
doi: 10.1016/S0090-1229(88)80004-7
pubmed: 2836115
Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78(9):1151–9.
doi: 10.1136/annrheumdis-2018-214819
pubmed: 31383717
Han HX, Qiu Y, Tian XL, Su W, Li J, Cao XX. A 47-Year-old woman with progressive exertional dyspnea and fatigue. Chest. 2022;161(2):e81–4.
doi: 10.1016/j.chest.2021.07.2178
pubmed: 35131077
Saccardo E, Novati P, Sironi D, Castelnovo L, Rinaldi G, Monti G. Causes of death in symptomatic cryoglobulinemia: 30 years of observation in a Department of Internal Medicine. Dig Liver Dis. 2007;39(Suppl 1):S52–54.
doi: 10.1016/S1590-8658(07)80011-9
pubmed: 17936224
De Vita S, Soldano F, Isola M, Monti G, Gabrielli A, Tzioufas A, Ferri C, Ferraccioli GF, Quartuccio L, Corazza L, et al. Preliminary classification criteria for the cryoglobulinaemic vasculitis. Ann Rheum Dis. 2011;70(7):1183–90.
doi: 10.1136/ard.2011.150755
pubmed: 21571735
Bombardieri S, Paoletti P, Ferri C, Di Munno O, Fornal E, Giuntini C. Lung involvement in essential mixed cryoglobulinemia. Am J Med. 1979;66(5):748–56.
doi: 10.1016/0002-9343(79)91112-4
pubmed: 443251
Ferri C, Sebastiani M, Giuggioli D, Cazzato M, Longombardo G, Antonelli A, Puccini R, Michelassi C, Zignego AL. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum. 2004;33(6):355–74.
doi: 10.1016/j.semarthrit.2003.10.001
pubmed: 15190522
Terrier B, Carrat F, Krastinova E, Marie I, Launay D, Lacraz A, Belenotti P, de Saint Martin L, Quemeneur T, Huart A, et al. Prognostic factors of survival in patients with non-infectious mixed cryoglobulinaemia vasculitis: data from 242 cases included in the CryoVas survey. Ann Rheum Dis. 2013;72(3):374–80.
doi: 10.1136/annrheumdis-2012-201405
pubmed: 22586172
Muchtar E, Magen H, Gertz MA. How I treat cryoglobulinemia. Blood. 2017;129(3):289–98.
doi: 10.1182/blood-2016-09-719773
pubmed: 27799164
Galli M, Monti G, Marson P, Scaini P, Pietrogrande M, Candela M, Castelnovo L, Faggioli P, Novati P, Zani R, et al. Recommendations for managing the manifestations of severe and life-threatening mixed cryoglobulinemia syndrome. Autoimmun Rev. 2019;18(8):778–85.
doi: 10.1016/j.autrev.2019.06.008
pubmed: 31181326
Quartuccio L, Bortoluzzi A, Scirè CA, Marangoni A, Del Frate G, Treppo E, Castelnovo L, Saccardo F, Zani R, Candela M, et al. Management of mixed cryoglobulinemia with rituximab: evidence and consensus-based recommendations from the Italian Study Group of Cryoglobulinemia (GISC). Clin Rheumatol. 2023;42(2):359–70.
doi: 10.1007/s10067-022-06391-w
pubmed: 36169798
Kondili LA, Monti M, Quaranta MG, Gragnani L, Panetta V, Brancaccio G, Mazzaro C, Persico M, Masarone M, Gentile I, et al. A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort. Hepatology. 2022;76(1):220–32.
doi: 10.1002/hep.32281
pubmed: 34919289